Long-term outcomes of homoharringtonine, cytarabine, daunorubicin or idarubicin (HAD/HAI) as induction chemotherapy in de novo acute myeloid leukemia
qin tie jun ;, xu ze feng ;, zhang yue ;, zuo ya ni ;, ru kun ;, fang li wei ;, zhang hong li ;, pan li juan ;, hu nai bo ;
..............page:94-99
..............page:100-104
..............page:105-109
..............page:110-114
..............page:115-118
..............page:119-123
..............page:124-129
..............page:130-133
..............page:134-137
..............page:138-143
..............page:144-148
..............page:149-151
..............page:151-153
..............page:154-156
..............page:157-159
..............page:160-163
..............page:164-168
..............page:169-173
..............page:174-176